NCT02859701View on ClinicalTrials.gov

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

May 17, 2017

Study Completion Date

May 17, 2017

Conditions
Healthy
Interventions
DRUG

AK002

IV AK002

OTHER

Placebo

Trial Locations (1)

Unknown

Nucleus Network Limited, Melbourne

Sponsors

Lead Sponsor

Allakos Inc.
All Listed Sponsors
lead

Allakos Inc.

INDUSTRY

NCT02859701 - Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants | Biotech Hunter | Biotech Hunter